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There is a pressing need to capture and track subtle cognitive change at the pre-
clinical stage of Alzheimer’s disease (AD) rapidly, cost-effectively, and with high sen-
sitivity. Concurrently, the landscape of digital cognitive assessment is rapidly evolv-
ing as technology advances, older adult tech-adoption increases, and external events
(i.e., COVID-19) necessitate remote digital assessment. Here, we provide a snapshot
review of the current state of digital cognitive assessment for preclinical AD includ-
ing different device platforms/assessment approaches, levels of validation, and imple-
mentation challenges. We focus on articles, grants, and recent conference proceed-
ings specifically querying the relationship between digital cognitive assessments and
established biomarkers for preclinical AD (e.g., amyloid beta and tau) in clinically nor-
mal (CN) individuals. Several digital assessments were identified across platforms (e.g.,
digital pens, smartphones). Digital assessments varied by intended setting (e.g., remote
vs. in-clinic), level of supervision (e.g., self vs. supervised), and device origin (personal
vs. study-provided). At least 11 publications characterize digital cognitive assessment
against AD biomarkers among CN. First available data demonstrate promising valid-
ity of this approach against both conventional assessmentmethods (moderate to large
effect sizes) and relevant biomarkers (predominantly weak to moderate effect sizes).
We discuss levels of validation and issues relating to usability, data quality, data pro-
tection, and attrition. While still in its infancy, digital cognitive assessment, especially
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when administered remotely, will undoubtedly play amajor future role in screening for
and tracking preclinical AD.
KEYWORDS
clinical assessment, clinical trials, cognition, computerized assessment, digital cognitive biomark-
ers, home-based assessment, preclinical Alzheimer’s disease, smartphone-based assessment
1 INTRODUCTION
In Alzheimer’s disease (AD), the major pathophysiological processes
(accumulation of amyloid beta protein [Aβ] into plaques assumed to
be followed by the aggregation of hyperphosphorylated tau protein [p-
tau]into neurofibrillary tangles [NFT]), begin years to decades prior to
the clinical dementia syndrome.1 During this preclinical phase, cogni-
tive functions are largely unaffected,2 but as neuropathological burden
increases over time, subtle cognitive decrements emerge.3 The pre-
clinical phase offers a promising window for preventing decline, which
emphasizes that capturing the subtle changes in cognition during this
phase is immensely important.4
1.1 Associations between paper-and-pencil
cognitive measures and AD biomarkers in preclinical
AD
In clinically normal (CN) individuals, abnormal levels of Aβ (Aβ+), as
measured in cerebrospinal fluid (CSF) (e.g., levels of Aβ42 or Aβ42/40)
or with positron emission tomography (PET) neuroimaging, are con-
sidered indicative of an early AD pathological process.2,3 During this
preclinical stage of the disease continuum, the cross-sectional asso-
ciation between Aβ and cognitive deficits is generally weak,5–8 or
insignificant.9–11 However,CN individualswithhigherAβburden (Aβ+)
exhibit faster cognitive decline,12–14 and often progress to a clini-
cal stage faster than those with lower levels of Aβ.15–18 This cogni-
tive decline is subtle and detectable only over several years. In one
study, Aβ+ CN participants declined at an average rate of −0.42 z-
score units per 18 months,19 while another study showed a decline
of between –0.07 and –0.15 average z-score units per year.20 The
strongest association between AD biomarkers and cognitive decline
is for memory function,21 but there are also reports of decline across
other cognitive domains,22,23 including executive24 and visuospatial
functions.25
The secondmajor pathogenic process in preclinical AD is tau aggre-
gation into NFT, also measurable in CSF (e.g., p-tau) and with PET
neuroimaging.1 Compared toAβ, tau has been consideredmore closely
linked to cognitive impairment during the AD process.26–28 In CN indi-
viduals, tau burden has been associated with memory impairment and
longitudinal cognitive decline.16,29,30 Given that tau PET is still rela-
tively newer than Aβ PET, less is known about the longitudinal relation
between tau and cognition, including later clinical progression. Gener-
ally, those with higher tau are at greater risk for longitudinal cognitive
decline; importantly, however, this decline is several fold faster in Aβ+
CN individuals.30–32
1.2 Paper-and-pencil versus digitized cognitive
assessment
The relationship between paper-and-pencil measures of cognition and
AD biomarkers among CN older adults is complex, but observed cor-
relations are generally relatively weak, particularly cross-sectionally.8
Longitudinally, these relationships aremore consistently observed and
of greater magnitude, with CN older adults with elevated biomarker
levels exhibiting cognitive decline.31,33 Weak relationships between
cognition and AD biomarkers may be partially attributable to the limi-
tations of paper-and-pencil assessments, most of which were designed
to detect frank impairment in clinical populations as opposed to being
designed to detect subtle preclinical impairment.34 Furthermore, nor-
mal fluctuations in cognitive performance,35 practice effects,36 and
cognitive reserve37 may obscure the detection of subtle cognitive
decline.
The use of digital technology to assess cognition has the poten-
tial to mitigate some of the limitations of current paper-and-
pencil assessments.38 For example, mobile devices enable more fre-
quent testing, resulting in more reliable and informative longitudi-
nal data39 and are more accessible and cost-effective thanks to self-
administration.40 Computerized measures that automatically gener-
ate alternative formsmay helpminimize practice and version effects.41
Artificial intelligence (AI) methods such as deep learning enable faster,
novel, and potentially more sensitive analysis of cognitive data.42
Digital assessments also pose new challenges. Many studies using
remote assessments struggle to maintain participant engagement.43
Digital storage and sharing of cognitive data pose questions related
to data privacy,44 particularly when devices may collect additional
identifiable personal data (e.g., voice recordings). Unsupervised digi-
tal assessments require systems to ensure the individual assigned to
a remote assessment is the individual taking that assessment. Rapidly
developing technologies and operating systems pose challenges to
selecting and maintaining a single version of a digital assessment over
time. Finally, while secular trends suggest that older adults are increas-
ingly familiar and comfortable with new technology,45 a not insignif-
icant population may be excluded from research with digital assess-
ments due to lack of familiarity, technical skills, or access.
Digital technology has not yet replaced paper-and-pencil assess-
ments, particularly not in clinical trials, because multiple questions
ÖHMAN ET AL. 3 of 19
HIGHLIGHTS
∙ Digital assessments for preclinical Alzheimer’s disease
(AD) vary by intended setting (e.g., remote vs. in-clinic),
level of supervision (e.g., self vs. supervised), and device
origin (personal vs. study-provided).
∙ At least 11 articles characterize digital cognitive assess-
ment in biomarker-defined preclinical AD, but the liter-
ature generally remains nascent, particularly for remote
and novel assessments.
∙ Multiple digital assessment instruments exhibit predomi-
nantly weak to moderate relationships with AD biomark-
ers in preclinical groups. More work is needed to con-
firm the concrete diagnostic potential in preclinical dis-
ease stages.
∙ Potential benefits and challenges are discussed within
the framework of future implementation in clinical trials,
including recommendations for future studies.
remain unanswered: Does digital technology capture cognitive infor-
mation analogous to gold-standard paper-and-pencil measures? Is
there a fundamental difference between capturing data with a rater
versus a device? How reliable and feasible is digital technology? These
questions are just beginning to be addressed in a more widespread
fashion as use of digital technology is rapidly evolving,46 for instance,
in research on preclinical AD.
1.3 Organization of results
In this context, our objectives were to systematically review the cur-
rent landscape of digital cognitive tests for use in preclinical AD and
to describe the extent of validation of these digital cognitive tests
against (1) gold-standard cognitive tests and test composites (paper-
and-pencil measures) and (2) biomarkers of Aβ and tau pathology. Fur-
thermore, we will critically discuss the potential and pitfalls of digital
cognitive assessments in the context of implementation in clinical tri-
als, and to provide an outlook for the future of digital cognitive assess-
ment. Our goal, however, was not to give an exhaustive overview of
mobile technology40 or computer testing47 for use in elderly popula-
tions in general. Additionally, we do not address the separate field of
passive monitoring to infer cognition using sensors andwearables.48
We first describe the current understanding of the associations
between cognitive performance on conventional paper-and-pencil
measures and AD biomarkers. Subsequently, we discuss digital assess-
ments organized into three groups based on technological platform
and/or setting: (1) primarily in-clinic computerized and tablet-based,
(2) primarily unsupervised environment and smartphone- or tablet-
based, and (3) novel data collection systems and analysis procedures
RESEARCH INCONTEXT
1. Systematic Review: The authors reviewed the literature
from sources such as PubMed, Scopus, and PsycINFO,
as well as grant and clinical trial databases and confer-
ence presentations. Publications reporting on novel, dig-
ital cognitive assessment methods in cognitively healthy
individuals characterized as preclinical Alzheimer’s dis-
ease (AD) by establishedbiomarker evidencewere appro-
priately cited and discussed.
2. Interpretation:We included and discussed different plat-
forms and approaches used to enable both on-site and
remotely administered digital assessment to identify
early cognitive impairment and decline in preclinical AD.
Their sensitivity to AD biomarkers was found ranging
frompredominantlyweak tomoderate. Several promising
newly developed assessment instruments were identi-
fied, currently under evaluation. Our findings have impli-
cations for the use of these instruments for the enrich-
ment of clinical trials with relevant participants.
3. Future Directions: This article emphasizes the potential
of novel assessment instruments to advance cognitive
assessment in the early identification of preclinical AD.
Before being fully implemented in clinical practice and
screening for clinical trials, however, further research is
needed to establish the concrete associations between
assessment outcome and established biomarkers sensi-
tive for the earliest signs ofADpathology. Last,we recom-
mend conducting feasibility studies to investigate poten-
tial barriers for future implementation.
(e.g., digital pen, eye-tracking, and language analysis; novelmethods for
data analysis, e.g., using AI approaches).
For each digital assessment, validation is discussed in terms of (1)
biomarker validation and (2) paper-and-pencil validation.
Paper-and-pencil validation involved comparing digital measures to
conventional measures such as relevant global cognitive composites




From January 2020 to December 2020, we searched three elec-
tronic databases (PubMed, Scopus, PsycINFO) for relevant publica-
tions (using search terms such as digital, mobile, smartphone, tablet,
Alzheimer’s, preclinical, amyloid), two online registers (ClinicalTri-
als.gov and National Institutes of Health [NIH] research portfolio) for
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relevant trials and awarded grants. A second search using the names of
digital tests and companies identified in the first searchwasperformed.
Wealso searched twoconferences for any relevant preliminary results:
Clinical Trials on Alzheimer’s Disease conference (CTAD) 2020 and
Alzheimer’s Association International Conference (AAIC) 2020.
2.2 Inclusion and exclusion criteria
Published articles, ongoing studies, and clinical trials using digital cog-
nitive assessment were selected if they involved individuals iden-
tified with preclinical AD. Preclinical AD was defined either based
on biomarker evidence of Aβ plaque pathology either by cortical Aβ
PET ligand binding or low CSF Aβ42 and/or NFT pathology (elevated
CSF p-tau or cortical tau PET ligand binding).1 Using the National
Institute on Aging and Alzheimer’s Association (NIA-AA) Research
Framework revised guidelines,2 we defined preclinical AD as corre-
sponding to the earliest stages in the numeric clinical staging (stage
1–2). We excluded studies that only included participants meeting cri-
teria for clinical diagnoses, such as mild cognitive impairment (MCI) or
dementia.
2.3 Procedures
A total of 469 articles were screened using the web-app Rayyan,49
of which 458 were excluded due to failure to meet inclusion criteria,
and 11 were included in the review. Grant applications were screened
from the NIH research portfolio, but no additional study was included.
Since this initial literature search, two additional newly published arti-
cles were included. Preliminary results from seven conference presen-
tations have also been included, specifically fromCTAD2020andAAIC
2020. The resulting relatively small, heterogeneous, and methodologi-
cally inconsistent body of literature limited our review’s methodology.
Therefore, we performed a qualitative synthesis rather than a meta-
analysis.
3 RESULTS
3.1 Primarily in-clinic computerized and
tablet-based cognitive assessment
Anestablished area of digital development in cognitive testing is adapt-
ing traditional cognitive measures onto computerized platforms such
as the Pearson’s Q-interactive for Wechsler Adult Intelligence Scale
or the Montreal Cognitive Assessment (MoCA) Electronic Test. Fur-
thermore, clinical trial data management companies such as Meda-
vante and Clinical Ink have adapted traditional cognitive measures
to be administered as electronic clinical outcome assessments. Auto-
matic scoring and recording mitigate common error sources, but these
systems, by definition, do not reimagine neuropsychological testing.
A number of computerized cognitive tests have been developed to
detect cognitive decline. These may include stand-alone apps and pro-
grams as well as web-based apps that can be completed either on
personal computers (PC) or tablets. Some of these tests consist of
digitized versions of traditional paper-and-pencil neuropsychological
tests, while others involve newly developed tests designed to be com-
pleted without the active participation or presence of an examiner;
these include, for example, Savonix, BrainCheck, Cogniciti, Mindmore,
BAC, NIH-Toolbox, CANTAB, and Cogstate, among others. Each vary in
their approach, degree of commercialization, security and regulatory
readiness, and degree of “gamification.” They also differ in their respec-
tive target populations and clinical indications. Here, we focus on the
systemsandplatforms specifically ormainlydesigned todetect theear-
liest cognitive decline in AD. See Table 1 for an overview of the valida-
tion of these types of cognitive assessment instruments. In Figure 1, a
selectionof primarily in-clinic computerizedand tablet-based cognitive
assessments are exemplified.
3.1.1 Cogstate digital cognitive testing system
Cogstate is a commercial company based in Australia. A founding prin-
ciple behind the Cogstate Brief Battery (CBB) was to mitigate the
effects of language and culture on cognitive assessment.50–52 There-
fore, their measures of response time, working memory, and con-
tinuous visual memory are completed using the universal stimulus
set of common playing cards. However, additional non–card-playing
tasks are also available (e.g., a paired associative learning task and a
maze learning task). This test battery was initially developed in the
early 2000s for PC (where participants would respond via keystrokes)
but is now available for tablets. A second founding principle behind
Cogstate tasks is a more reliable measurement of change over time
through randomized alternative versions to reduce confounding prac-
tice effects. The Cogstate system was initially designed to be adminis-
tered by an examiner, but there have been recent efforts for remote
administration; additionally, once logged into the platform, the tasks
are easy to progress through independently. Recently, the CBB has
been made available for unsupervised testing using a web browser. A
recent report53 from the Healthy Brain Project in Australia showed
high acceptability and usability for this unsupervised cognitive testing
in a non-clinical sample. They observed low rates of missing data and
the psychometric characteristics of the CBB were similar to those col-
lected from supervised testing.
A more recent iteration of Cogstate tasks is the C3 (Computer-
ized Cognitive Composite) which includes the CBB in addition to two
measures potentially sensitive to changes in early AD based on evi-
dence from the cognitive neuroscience literature: the Behavioral Pat-
tern Separation–Object Version (BPS-O) and The Face-Name Associa-
tive Memory Test (FNAME). Behavioral versions of the FNAME54 and
amodified version of theBPS-O55 were selected for inclusion in theC3
as they have been shown sensitive to activity in the medial temporal
lobes in individuals at risk for AD based on biomarkers.56,57
In a large sample of older adults (n = 4486), C3 performance was
shown to be moderately correlated with cognitive performance on
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F IGURE 1 A, Cogstate One Back tests. Copyright© 2020 Cogstate. All rights reserved. Usedwith Cogstate’s permission. B, CANTAB Spatial
Span and Paired Associates Learning. Copyright Cambridge Cognition. All rights reserved. C, NIH-Toolbox Pattern Comparison Processing Speed
Test Age 7+ v2.1. Usedwith permission NIH Toolbox, © 2020National Institutes of Health andNorthwestern University
a composite of paper-and-pencil measures (PACC).7 A smaller study
similarly showed this correlationbetween theC3andpaper-and-pencil
measures.58 It also showed that the Cogstate C3 battery’s memory
tasks were best at identifying individuals’ subtle cognitive impair-
ment, as defined by PACC performance. Combined, these findings sug-
gest that these computerized tasks are valid measures of cognitive
function and may be used for further study of cognitive decline in
preclinical AD.
The Cogstate test batteries are used in several ongoing studies
and clinical trials, for example, the Wisconsin Registry for Alzheimer’s
Prevention (WRAP), Alzheimer’s Disease Neuroimaging Initiative 3
(ADNI3), Cognitive Health in Ageing Register: Cohort Study, and the
Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU). The
C3 is currently being used in the Anti-Amyloid Treatment in Asymp-
tomatic Alzheimer’s Disease (A4) study and the Study to Protect Brain
Health Through Lifestyle Intervention to Reduce Risk.
Preclinical AD biomarker validation
Screening data from the A4 study showed that, among a large sam-
ple of CN elderly, elevated Aβ as assessed with [18F]florbetapir-PET
was associated with slightly worse C3 performance.7 Other obser-
vational studies have not shown associations between CBB perfor-
mance and Aβ status in preclinical AD cross-sectionally,51 but some
studies have demonstrated that Aβ+ individuals decline on CBB over
time. For example, in the Australian Imaging, Biomarkers and Lifestyle
(AIBL) study, decline in episodic and working memory over 36 months
was associated with higher baseline Aβ burden in CN participants.13
Researchers from the Mayo Clinic Study on Aging used similar meth-
ods in a population-based sample, and in contrast, they did not find any
significant associationbetweenAβ andCBBdecline.59 In another study
from AIBL, performance on a continuous paired associative learning
task (CPAL) within the Cogstate battery was explored for Aβ+ and
Aβ– CN. Over 36 months, Aβ– task performance improved over time,
whereas Aβ+ showed no practice effect. In CN, the absence of bene-
fit from repeated exposure over time was associated with a higher Aβ
burden.60
3.1.2 The computerized National Institutes of
Health Toolbox Cognition Battery (NIH-TB)
TheNational Institutes of Health (NIH) Toolbox Cognitive Battery (TB-
CB) was designed as an easily accessible and low-cost means to pro-
vide researchers with standard and brief cognitive measures for vari-
ous settings. Development of the NIH TB-CB was a large-scale effort
across government funding, scientists (250+), and institutions (80+).61
It consists of seven established neuropsychological tests, selected and
adapted to a digital platform by an expert panel. The NIH TB-CB tests
assess a range of cognitive domains (attention and executive func-
tions, language, processing speed,workingmemory, and episodicmem-
ory). It was released in 2012 for PC, and a tablet version is now also
available that has been validated against standard neuropsychological
measures,62 aswell as against established cognitive composites for use
in preclinical AD.58 To ensure valid results, an examiner is still required
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to administer the app; however, some tests have recently been
implemented for remote administration via screen sharing in a web
browser.
The NIH TB-CB is currently implemented in several clinical trials
and longitudinal studies in aging and early AD, for example, in the
Risk Reduction for Alzheimer’s Disease study, the Comparative Effec-
tiveness Dementia & Alzheimer’s Registry, and the ongoing project
Advancing Reliable Measurement in Alzheimer’s Disease and Cogni-
tive Aging (ARMADA). The latter study, ARMADA, is an NIH-funded
largemulti-site project in the United States, aiming to validate the NIH
Toolbox in several demographically diverse CN and clinical cohorts,
including earlier underrepresented demographical groups. ARMADA’s
additional goals are to further facilitate the use of NIH TB-CB in aging
research through the formation of a consortium with the National
Alzheimer’s CoordinatingCenter and in collaborationwith researchers
from other existing cohorts.
Preclinical AD biomarker validation
There are a handful of studies examining NIH TB-CB in aging and
dementia populations; however, there is currently a limited number
of published studies on NIH TB-CB and preclinical AD biomarkers. A
recent study in118CNolder adults did not find anassociationbetween
AD neuroimaging markers of Aβ and any of the NIH TB-CB cognitive
tasks. However, they did find a weak association between measures of
processing speed and executive functions and higher Braak regions of
tau pathology.63
3.1.3 The Cambridge Neuropsychological Test
Automated Battery (CANTAB)
The Cambridge Neuropsychological Test Automated Battery
(CANTAB) is intended as a language-independent and culturally
neutral cognitive assessment tool initially developed by the University
of Cambridge in the 1980s, but now commercially provided by the
company Cambridge Cognition. CANTAB has been used in a wide
range of clinical settings and clinical trials,64 including aging studies.65
CANTAB mostly uses non-verbal stimuli, and it includes measures of
working memory, planning, attention, and visual episodic memory.
Administration of CANTAB was initially on PC but is now available
through CANTAB mobile (tablet-based). Additionally, CANTAB offers
an online platform for recruitment by pre-screening patients using
their cognitive assessment instruments.
Preclinical AD biomarker validation
In the Dallas Lifespan Brain Study, CN individuals underwent Aβ PET
with [18F]florbetapir) and theCANTABVerbalRecognitionTest, includ-
ingmeasures of memory recall and recognition. In this test, the partici-
pants are shown a sequence of words on a touchscreen. Subsequently,
the participant is asked to recall the words, and the task ends with
a recognition task. The researchers found that in relatively younger
adults (30 to 55), higherAβwasmoderately associatedwith diminished
memory recall and recognition,whereas the effectweakened as people
aged and amyloid levels increased.66
3.2 Remotely administered tablet- and
smartphone-based cognitive assessment
Demographic survey trends in the United States from 2019 indicated
that 77% of Americans aged 50+ own smartphones67 with that num-
ber climbing annually.68 Similar numbers are being reported from
European countries.69 Simultaneously, there has been an increase in
smartphone-based apps designed for cognitive assessment in older
populations.40 The appeal and implication of smartphone-based cogni-
tive assessment for detection and tracking in preclinical AD are obvi-
ous. It is highly scalable, allowing for remote assessment in a much
larger population compared to samples acquired through in-clinic and
supervised assessment. It allows for more frequent assessment with
potentially more sensitive cognitive paradigms.70 With mobile tech-
nology, cognitive assessment can be performed in a familiar environ-
ment and may thus increase the ecological validity (i.e., the generaliz-
ability to real-life setting) of the task. Having a participant complete
tasks on their own phone (as opposed to a study-issued device) may
bemore reflective of their cognition in everyday life. Improved ecolog-
ical validity of smartphone-based assessment is timely, as researchers
and regulators emphasize the importance of demonstrating the clinical
meaningfulness of cognitive change in a preclinical AD population. Fur-
thermore, the participant being in a familiar environment during cogni-
tive assessmentsmay reduce the risk of the "white-coat effect” (partic-
ipants underperforming on tasks in a medical environment).71 Remote
and mobile tracking of cognitive functioning provide an extra oppor-
tunity for an individual to track their own cognitive health over time,
potentially leading to increased commitment to their well-being.72
Finally, for those willing to participate in demanding clinical trials,
reducing in-clinic visits through remote testingmaymitigate theoverall
participant burden and encourage those in more remote areas to par-
ticipate.
However, despite the potential of smartphone-based assessment,
multiple issues remain, including challenges related to (1) feasibility
(e.g., older adults’ openness to completing smartphone assessments,
compliance, attrition, privacy issues), (2) validity (e.g., ensuring align-
ment between smartphone-based vs. gold standard cognitive assess-
ment data, guaranteeing the identity of the examinee), and (3) reliabil-
ity (e.g., variability between hardware and operating systems, dimin-
ished control over the test-taking environment).
Given the recent rapid expansion of interest in this area, we focus
on observed themes for smartphone-based instruments that are in
early (but varying) stages of development. Identified themes include (1)
improving reliability of assessment through ambulatory/momentary
testing, (2) usingmobile and serial assessment to identify subtle decre-
ments in learning and practice effects, (3) targeting cognitive pro-
cesses more specific to decline in preclinical AD, (4) and harnessing
the potential of big-data collection. Validity data in relation to in-clinic
cognitive assessment and AD biomarkers is discussed where available.
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F IGURE 2 A, Ambulatory Research in Cognition (ARC) Symbols Test, Grids Test, and Prices Test. Usedwith permission from J. Hassenstab. B,
neotiv Objects-in-Rooms Recall test. Usedwith permission from neotiv GmbH. C, Boston Remote Assessment for Neurocognitive Health
(BRANCH). Usedwith permission fromK. V. Papp
See Figure 2 for selected examples of smartphone-based assessment
applications. Table 2 displays the validation of remotely administered
tablet- and smartphone-based cognitive assessments.
3.2.1 Feasibility of using mobile devices to capture
cognitive function
While retention in longitudinal study designs is especially challenging
for studies using remotely administered testing, adherence in short
studies is promising. In a recent study, 1594 CN subjects (age = 40
to 65) completed a testing session using a web-based version of four
playing card tasks within the Cogstate battery.53 High adherence
to instructions and low rates of missing data were observed (1.9%),
indicating high acceptability. Error rates were consistently low across
tests and did not vary due to the self-reported environment (e.g., with
others present or in a public space). Another recent study investigated
adherence during 36 days using a smartphone-based app.73 Thirty-five
CN participants (age = 40 to 59) completed very short daily cognitive
tasks, where 80% completed all tasks, with 88% of the participants
still active at the end of the study. More problematic, a recent report
from eight digital health studies (providing study-app usage data
from > 100,000 participants) in the United States describes substan-
tial participant attrition (e.g., participants losing engagement over
time), confounding the generalizability of data obtained.43 Monetary
compensation improved retention, and boding well for preclinical
AD studies, older age was associated with longer study participation
duration. However, participants involved in trials that included in-clinic
visits had the highest compliance, suggesting that attrition in fully
remote longitudinal studies remains a significant challenge.
3.2.2 Improving reliability: ambulatory/momentary
cognitive assessment
The premise behind ambulatory/momentary cognitive assessment is
that single-timepoint assessments fail to capture the endemic vari-
ability in human cognitive performance impacted by a host of factors,
including mood, stress, or time of day.35 Capturing the most repre-
sentative sample of an individual’s cognition at a given interval is one
promising approach to improving the sensitivity of measurement by
reducing variability and increasing reliability. Using a “burst” design, a
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more reliable composite measure of cognitive performance is derived
by averaging performance overmultiple assessment timepoints admin-
istered in short succession (e.g., four assessments per day for 7 days).
Sliwinski et al. developed the brief smartphone-based app Mobile
Monitoring of Cognitive Change (M2C2) aimed at capturing cogni-
tion more frequently in an uncontrolled and naturalistic setting.39 In
a younger (age 25 to 65) but highly diverse (9% White) sample, they
showed that brief smartphone-based cognitive assessments of percep-
tual speed and working memory in an uncontrolled environment were
correlated with in-clinic cognitive performance.39 The proportion of
total variance in performance attributable to differences betweenpeo-
ple (accounting forwithin-person variance across each test session and
number of test sessions) was high, illustrating the excellent level of reli-
ability achieved using a burst design.
Similarly, Hassenstab designed the Ambulatory Research in Cogni-
tion app (ARC) for use in the DIAN study.74 In contrast with previous
studies that have relied on study-provided devices,39,75 participants
download the app onto their own devices and indicate the days and
times they are available to be tested. Participants subsequently receive
notifications to takeARC,which lasts a fewminutes, 4 times per day for
1 week. ARC evaluates working spatial memory (Grids Test), process-
ing speed (Symbols Test), and associativememory (Prices Test). Prelim-
inary results suggest that ARC is reliable, correlated with in-clinic cog-
nitive measures and AD biomarkers, and well-liked by participants.74
Further work is required to determine whether ambulatory cognitive
data are (1)more strongly related toAD-biomarker burden inCNolder
adults compared to conventional in-clinic assessments and (2) whether
these data represent a more reliable measure of cognitive and clinical
progression compared to conventional in-clinic assessments.
3.2.3 Using mobile and serial assessment to
identify subtle decrements in learning and practice
effects
A diminished practice effect, that is, a lack of the characteristic
improved performance on retesting, has been suggested as a subtle
indicator of cognitive change prior to overt decline.76 Mobile tech-
nology allows for much more frequent serial assessment. For exam-
ple, a recent study provided iPads to 94 participants to take home and
to complete a monthly challenging associative memory task requiring
memory for face-namepairs (FNAME) for 1 year.77 They foundanasso-
ciation between diminished learning and greater amyloid and tau PET
burden among CN, with the Aβ ± group differences in memory perfor-
mance emerging by the fourth exposure.
Work using a web-based version of FNAME78 and other mem-
ory tasks, called the Boston Remote Assessment for Neurocognitive
Health (BRANCH), was designed to move learning paradigms from
study-provided tablets to smartphones and to reduce the time inter-
val for serial assessment (e.g., from months to days). These tasks focus
on cognitive processes supported by the medial temporal lobes and
thus best able to characterize AD-related memory changes. BRANCH
primarily consists of measures of associative memory, pattern sepa-
ration, and semantically facilitated learning and recall. BRANCH also
uses paradigms and stimuli relevant to everyday cognitive tasks.79
In a similar vein, the Online Repeatable Cognitive Assessment-
Language Learning Test (ORCA-LLT) developed by Dr. Lim at Monash
University in Australia, asks participants to learn the English word
equivalents of 50 Chinese characters for 25 minutes daily over 6 days.
The task is web-based and completed on a participant’s own device in
their home. They found that learning curveswere diminished in 38Aβ+
versus 42 Aβ– CN older adults, and the magnitude of this difference
was very large.80
The assessment of learning curves over short time intervals using
smartphones may serve as a cost-effective screening tool to enrich
samples for AD biomarker positivity prior to expensive assays. For
example, a clinical study found that lower practice effects over 1 week
were associated with a nearly 14 times higher odds of being Aβ+
on a composite measure using [18F]flutemetamol.81 Future work with
largerCN samples and further optimized learning paradigmsmay show
similar discriminability properties of learning curves to AD biomarker
positivity in a preclinical sample. Capturing learning curves over short
intervals using remote smartphone-based assessment may provide a
more rapid means of assessing whether a novel treatment has ben-
eficial effects on cognition. This could assist in more rapidly discon-
tinuing futile treatment trials or, more importantly, trials with dele-
terious effects on cognition.82 However, how the repeated measures
of short-term learning curves can be used to track cognitive progres-
sion remains unexplored. Methods to establish this relationship are in
development but will require validation studies to overcome logistical
and technical challenges.
3.2.4 Targeting relevant cognitive functions
While there is significant heterogeneity in the nature and progres-
sion of cognitive decline within AD, the availability of AD biomark-
ers and adoption of findings from the cognitive neuroscience litera-
ture have allowed researchers to hone in on cognitive processes poten-
tially more sensitive and specific to AD. For example, researchers from
theOtto-von-Guericke University inMagdeburg and the German Cen-
ter for Neurodegenerative Diseases (DZNE) have been involved in the
development of a digital platform including a mobile app for smart-
phones and tablets (neotiv), which consists of memory tests focused
on object and scenemnemonic discrimination,83 pattern completion,84
face-name association,85 and complex scene recognition.86 The object
and scenemnemonic discrimination paradigmwas designed to capture
memory function associated with an object-based (anterior-temporal)
and a spatial (posterior-medial) memory system.87 While functional
magnetic resonance imaging (fMRI) studies have shown that both
memory systems were activated in individuals performing the task,
age-related and performance-dependent changes in functional activity
havebeenobserved in the anterior temporal lobe inolder adults.83 Fur-
thermore, two studies in biomarker-characterized individuals revealed
that objectmnemonic discrimination performancewas associatedwith
measures of tau pathology (i.e., anterior temporal tau-PET binding and
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CSFp-tau levels),while therewas evidence for an associationof perfor-
mance in the scene mnemonic discrimination task with Aβ-PET signal
in posterior-medial brain regions.88,89 The complex scene recognition
taskhasbeen shown to rely onawider episodicmemorynetwork86 and
task performancewas associated with CSF total-tau levels.90 All of the
above tests have been implemented in a digital platform for unsuper-
vised testing using smartphones and tablets. Recently, relationships of
these tests and biomarkers for tau pathology aswell as strong relation-
ships with in-clinic neuropsychological assessments have been demon-
strated (i.e., Alzheimer’s Disease Assessment Scale-Cognitive subscale
delayedword recall, PACC).91,92
Participants download the app onto their own mobile devices and
undergo a short introduction and training session as well as a short
vision screening. Participants subsequently receive notifications to
complete tests according to apredefined study schedule to acquire lon-
gitudinal trajectorieswith high frequency. Tominimize practice effects,
stimulus material has been piloted in large scale web-based behavioral
assessments, and parallel test sets with matched task difficulty have
been created.93 The neotiv platform is currently included in several AD
cohort studies (e.g., DELCODE, BioFINDER-2, andWRAP).
3.2.5 Harnessing the potential of “big data”: citizen
science projects
Citizen science is a concept in which the general public is involved in
collaborative projects, for example, by collecting their own data for use
in research,94 and can be away to gather large amounts of data on indi-
viduals at risk of developingAD.One such citizen science project is The
Many Brains Project, with their research platform TestMyBrain.org.95
The Many Brains Project has yielded some of the largest samples in
cognition research, with more than 2.5 million people tested since
2008; however, the study is not specific toAD.Another study, theMod-
els of Patient Engagement for Alzheimer’s Disease study, is an EU-
funded international initiative aiming to identify individuals with early
AD hidden in their communities and traditionally not found in memory
clinic settings.96 Through web-based cognitive screening instruments,
individuals from the public with a heightened risk of AD are identified
and invited to amemory clinic to undergo a full diagnostic evaluation.
At the Oxford University’s Big Data Institute, researchers have
developed the smartphone app Mezurio, included in several European
studies (e.g., PREVENT, GameChanger, Remote Assessment of Disease
and Relapse in Alzheimer’s Disease study, BioFINDER-2). One of them,
GameChanger, is a citizen science project with more than 16,000 par-
ticipants from the general UK population completing remote, frequent
cognitive assessments with the Mezurio app. Through this project,
healthy volunteers can perform tests on their smartphones, thus pro-
viding population norms for different age groups and demographic
groups.Mezurio is installed on a smartphone and has several game-like
tests examining episodic memory (Gallery Game and Story Time), con-
nected language (Story Time), and executive function (Tilt Task), includ-
ing multiple recall tasks, and longer delays of up to several days. In
a recent study investigating the feasibility of Mezurio in middle-aged
participants, the participants demonstrated high compliance indicating
that this appmay be suitable for longitudinal follow-up of cognition.73
In Germany, Dr. Berron et al. from the German Center for Neurode-
generative Diseases (DZNE) developed a Germany-wide citizen sci-
ence project (“Exploring memory together”) focused on the feasibility
of unsupervised digital assessments in the general population. Besides
demographic factors that affect task performance, there are several
factors in everyday life (e.g., taking the test in the evening compared to
during the day) that could contribute to performance on remote unsu-
pervised cognitive assessments. Preliminary results from more than
1700 participants (ages 18 to 89) identified important factors that
need to be considered in future remote studies, including time of day,
the time between learning and retrieval, and (for one task) screen size
of the mobile device. They concluded that investigating memory func-
tion using remote and unsupervised assessments is feasible in an adult
population.97
3.3 Novel data collection systems and analysis
procedures
Other promising assessment instruments under evaluation in different
studies on preclinical AD are the analyses of spoken language, eye
movements, spatial navigation performance, and digital pen stroke
data. Some of these tasks require stand-alone equipment (e.g., eye-
tracker, digital pen), while others can use existing platforms or devices
(e.g., device-embedded cameras,98 such as those in a personal laptop
or the front-facing camera on a smartphone). Figure 3 exemplifies
some of these assessment instruments. Table 2 displays the validation
of novel types of assessment instruments. Some instruments, such as
commercial-grade eye-tracking cameras, or digital pens, are still not
widely accessible, hampering their implementation. Predominantly
passive monitoring of cognition, such as speech recording and eye
movement-tracking, may prove less stressful and time-consuming than
conventional cognitive tests. Participants complete a task of objective
cognition (e.g., drawing a clock, or describing a picture) while subtle
aspects of their performance are being recorded (e.g., pen strokes,
eye movements, language). The result is a large quantity of data about
performance, which must then be reduced or synthesized to glean
relevant performance features. Using machine learning (ML) or deep
learning, researchers have started to investigate whether automated
analyses and classification of test performance according to specific
criteria (e.g., biomarker or clinical status) can aid in sensitive screening
in preclinical AD.99,100 In a clinical context, ML can be used as a clinical
decision support system, building prediction models that achieve high
accuracy in clinical diagnosis and selecting patients for clinical trials at
the early stages of dementia development.101,102
3.3.1 Spoken language analysis and automated
language processing
New technical developments have provided further insight into lan-
guage deficits in preclinical AD, and several newly developed analysis
12 of 19 ÖHMAN ET AL.
F IGURE 3 A, Sea HeroQuestWayfinding and Path integration. Usedwith permission fromM. Hornberger. B, Digital Maze Test from survey
perspective and landmarks from a first-person perspective. Usedwith permission fromD. Head. C, Data and analysis process for digital Clock
Drawing Test (dCDT), from data collection, the artificial intelligence (AI) analysis steps, and themachine learning (ML) analysis and reporting. Used
with permission fromDigital Cognition Technologies
instruments are now available.103 For these instruments, speech pro-
duction is usually recorded during spontaneous speech; verbal fluency
tasks; or describing a picture, typically using the Cookie Theft picture
from the Boston Diagnostic Aphasia Examination.104 Speech is typi-
cally recorded using either a stand-alone audio recorder or embedded
microphone, and after that, transcribed and analyzed using computer
software. For example, using a picture task, researchers can analyze
speech, such as verbs and nouns in spontaneous speech; the complex-
ity of sentences, as represented by grammatical complexity and verb
usage; diversity of words; and the flow of speaking, such as speech rep-
etitions and pauses.105
Transcription of speech to text, a vital part of speech analysis,
is by definition time consuming, but there has been an increasing
effort to apply machine- and deep-learning technology to detect cog-
nitive impairment in AD. For example, researchers from the Euro-
pean research projectDem@care and theEITDigital project ELEMENT
demonstrated that automated analysis of verbal fluency could distin-
guish between healthy aging and clinical AD,106 as well as vocal anal-
ysis using smartphone apps for automatic differentiation between dif-
ferent clinical AD groups.107 In the latter, speech was recorded while
performing short verbal cognitive tasks, including verbal fluency, pic-
ture description, counting down, and a free speech task. Thereafter, it
was used to train automatic classifiers for detectingMCI andAD, based
on ML methods. The question is still whether they can identify early
cognitive impairment and decline in preclinical AD.
Intensive development of these methods is ongoing at sev-
eral research sites. For example, researchers are exploring subtle
speech-related cognitive decline in early AD through the European
Deep Speech Analysis (DeepSpA) project. The DeepSpA project uses
telecommunication-based assessment instruments for early screening
and monitoring in clinical trials, using remote semiautomated anal-
ysis methods. In the United States, researchers in the Framingham
Health Study are recording and analyzing speech obtained during neu-
ropsychological assessments (from 8800+ neuropsychological exam-
inations from 5376+ participants). Similarly, in Sweden, researchers
are recording speech (1000+ participants) during neuropsychologi-
cal assessments in the Gothenburg H70 Birth Cohort Studies. The
studies mentioned above are in cooperation with the company ki ele-
ments, a spin-off of the German Research Center for AI. Another com-
pany, Canadian Winterlight Labs, has developed a tablet-based app to
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identify cognitive impairment using spoken language. The app is cur-
rently being evaluated in the Winterlight’s Healthy Aging Study, an
ongoing longitudinal normative study.
Preclinical AD biomarker validation
While most researchers have investigated MCI patients,108
researchers from the Netherlands-based Subjective Cognitive
Impairment Cohort recorded spontaneous speech in CN individuals
performing three open-ended tasks (e.g., describing an abstract paint-
ing). After manual transcription, the researchers extracted linguistic
parameters using a fully automated freely available software (T-Scan).
Using conventional neuropsychological tests, the participants per-
formed within normal range, regardless of Aβ status (either using CSF
Aβ1-42 or [18F]florbetapir-PET). Interestingly, a modest correlation
was seen between abnormal Aβ and subtle speech changes (fewer
specific words).109
3.3.2 Eye-tracking
In AD research, commercial-grade eye-tracking cameras have been
shown to detect abnormal eye movements in clinical groups.110,111
These are high frame rate cameras managing to collect a wealth of
data on eye movement behavior, including saccades (simultaneous eye
movements), and fixation (eyes focusing on areas). Eyemovements can
be recorded within specific tasks, for example, reading a text or per-
forming a memory test. For example, Peltsch et al.110 measured the
ability to inhibit unwanted eye movements within a task using visual
stimuli. This data can, in turn, be analyzed automatically using com-
mercial software or inspected manually by researchers. However, eye-
tracking devices are so far expensive and are not widely available in
clinical settings. A solution for this may be the use of device-embedded
cameras (e.g., in a laptop or tablet) to capture eye-movement during
tasks, such as performing memory tests. Bott et al.112 from the com-
pany Neurotrack Technologies showed that device-embedded cam-
eras (i.e., in a PC), which are low cost and have high scalability, are
feasible to capture valid eye-movement data of sufficient quality. In
this study, eye movements were recorded in CN participants during a
visual recognition memory task. They observed a modest association
between eye movements and cognitive performance on a paper-and-
pencil composite. Interestingly, both device-embedded cameras and
commercial-grade eye-tracking cameras showed robust data of suffi-
cient quality. This suggests that device-embedded eye-tracking meth-
ods may be useful for further study of AD-related cognitive decline in
CN. Besides accuracy of performance, eye trackers yield data on addi-
tional eye movement behaviors, opening opportunities for new types
of potentially meaningful outcomes.
3.3.3 Digital pen
Digital pens look like regular pens but have an embedded camera
and sensors that can capture position and pen stroke data with high
spatial and temporal resolution. Outcomes include time in air and sur-
face, velocity, and pressure. This results in the collection of hundreds
or thousands of datapoints and variables in contrast with traditional
paper-and-pencil measures wherein point estimates of reaction time
and accuracy are the primary outcomes. Big-data techniques such as
ML can then be applied to these datasets to extract relevant signal. For
example, Digital Cognition Technologies captured data from thousands
of individuals completing the standard clock drawing test. They sub-
sequently developed the digital Clock Drawing Test (dCDT),100 which
features an extensive scoring system based on ML techniques that
describes performance outcomes related to information processing,
simple motor functioning, and reasoning (among many others). This
approach allows researchers to capture an individual’s inefficiencies in
completing a cognitive task despite overall intact performance, which
has the potential to collect and analyze much more subtle aspects of
behavior systematically.
Preclinical AD biomarker validation
Preliminary results from a study of older adults found that worse per-
formance on dCDT, particularly on a visuospatial reasoning subscore,
was associated with greater Aβ burden on PET and exhibited better
discrimination between those with high versus low Aβ in contrast with
standardneuropsychological tests included in amulti-domain cognitive
composite.113
3.3.4 Virtual reality and spatial navigation
In virtual reality (VR)-based tests, participants perform tasks of varying
complexity in computer-generated environments. These tasks are tra-
ditionally presented on computer screens (e.g., laptops or tablets) with
which participants interact using a joystick, keyboard, touch screen, or
VR head-mounted display. The Four Mountains Test is an example of a
VR-based test, available for use on iPad. Itmeasures spatial function by
alternating viewpoints and textures of the four mountains’ typograph-
ical layout within a computer-generated landscape. The clinical useful-
ness of the test has been demonstrated in clinical studies;114,115 how-
ever, its relation to preclinical AD biomarkers is still unknown. Another
example is a VR path integration task, developed by researchers from
CambridgeUniversity. In this task, participants are asked toexplorevir-
tual open arena environments. Using a professional-grade VR headset,
the participants are then asked to walk back to specific locations. In a
clinical study,116 it was superior to other cognitive assessments in dif-
ferentiatingMCI fromCN, andwas correlated toCSFbiomarkers (total
tau and Aβ). This task is currently being evaluated in a preclinical popu-
lation with biomarker data.
The launch of the online mobile game Sea Hero Quest yielded great
interest, and as of today, > 4.3 million people have played it. Deutsche
Telekom collaborated with scientists from University College London
and University of East Anglia to create this mobile game. The idea
is to gather data to create population norms from several countries,
enabling the development of easily administered spatial navigation
tasks to detect AD. Preliminary results suggest that Sea Hero Quest
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is comparable to real-world navigation experiments, suggesting that it
does not only capturemere video gaming skills.117
Preclinical AD biomarker validation
In a recent study, performanceon the SeaHeroQuestmobile gamewas
found to discriminate healthy aging from genetically at-risk individuals
of AD. They used SeaHeroQuest performance in a smaller apolipopro-
tein E (APOE) genotyped cohort. Despite having no clinically detectable
cognitive deficits, individuals genetically at risk performed worse on
spatial navigation. Wayfinding performance was able to discriminate
between APOE carriers and non-carriers.118
In another study, participants from the Knight Alzheimer’s Disease
Research Center underwent a virtual maze taskmeasuring spatial nav-
igation. This virtual maze was created using commercial software and
is presented on a laptop, participants maneuvering through a joystick.
The mazes consist of a series of interconnected hallways with several
landmarks. Their findings indicated that Aβ+ positivity (CSF Aβ42+)
was associated with lower wayfinding performance. For inclusion in
future studies, the spatial navigation task has been made available for
remote use through aweb-based interface.119
4 DISCUSSION
In this systematic review, several digital assessments were identified
on multiple delivery platforms (e.g., tablets, smartphones, and exter-
nal hardware), intended to measure cognition or behaviors in preclin-
ical AD (see Figure 4 for an overview of assessments and their plat-
forms). These assessment instruments varied by intended setting (e.g.,
remote vs. in-clinic), level of supervision (e.g., self vs. supervised), and
device origin (personal vs. study-provided). Studies validating assess-
ment instruments for more established platforms (e.g., PC, tablet) are
more common than those developed for more novel platforms (e.g.,
smartphone). However, many of these newly developed tests are cur-
rently being evaluated in several biomarker studies.
4.1 Validation with biomarkers of AD pathology
A critical part of early detection of preclinical AD in CN is the abil-
ity of cognitive tests to identify evidence of subtle cognitive impair-
ment or decline over time. Primarily in-clinic administered tests have
demonstrated a cross-sectional relationship to preclinical ADbiomark-
ers, in parity with traditional neuropsychological assessment, with
weak tomoderate effect sizes. Longitudinal studies using conventional
paper-and-pencil assessments aremixed, butmost demonstrate subtle
declines in preclinical phases of AD. Remotely administered tests, on
the other hand, have been less explored, butwork from several preclin-
ical biomarker studies is underway. A handful of validation studies in
the literature and preliminary results of a smartphone-based memory
test show a relationship to tau pathology.91 In a small but promising
study using a remotely administered web-based assessment of learn-
ing, learning curves in Aβ+ were significantly slower than those in
F IGURE 4 Overview of cognitive tests and their platforms.
BRANCH, Boston Remote Assessment for Neurocognitive Health;
ORCA-LLT, Online Repeatable Cognitive Assessment-Language
Learning Test; NIH-TB, National Institutes of Health Toolbox;
CANTAB, Cambridge Neuropsychological Test Automated Battery;
ARC, Ambulatory Research in Cognition;M2C2,Monitoring of
Cognitive Change; dCDT, digital Clock Drawing Test. *Is available for
use through aweb browser
Aβ–, warranting further study of this approach.80 Other novel assess-
ment instruments, including speech analysis,109 eye-tracking,112 and
VR,118,119 have demonstrated potential usefulness for further study of
relevant preclinical AD biomarkers. Interestingly, preliminary results
using a digital clock drawing test has shown high sensitivity to changes
among CN individuals with positive AD biomarkers.113
Future longitudinal studies should include longitudinal biomarker
data, also exploring the validity for changing biomarkers over time.
Future studies also need to investigate the ability to detect clinical pro-
gression, that is, from preclinical AD to MCI and dementia, warranting
extensive longitudinal studies of CN individuals.
4.2 Validation with established cognitive
composites
In addition to validation using preclinical AD biomarkers, an alterna-
tive means of validation is to compare digital assessments against con-
ventional cognitive measures used in large-scale studies. This type of
validation can supplement biomarker studies or provide important pre-
liminary data before using more costly biomarker studies. A handful of
assessment instruments, including a tablet-based test,58 eye-tracking
assessment,112 and a smartphone app,92 have been validated against
relevant global cognitive composites, indicating some validity for fur-
ther study of biomarkers in preclinical AD. However, as the correlation
between conventional composites and preclinical AD is already weak,
pen-and-paper validation alone is not enough to be able to claim that
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a test is suitable as a measure of subtle cognitive changes in preclinical
AD.
4.3 Potential of digital cognitive assessment
instruments in different settings
The contexts in which new technology is being used impose differ-
ent requirements on a test’s capabilities. The requirements are, for
instance, higher if the test results are outcomes in a clinical study than
if used for participant selection for inclusion into studies. Tablet-based
tests, similar to traditional cognitive test batteries, have already been
implemented in clinical trials. They are primarily intended to be admin-
istered with the help of a trained rater. Unsupervised and remotely
administered tests have not yet shown sufficient robustness to be used
in this context, and there remain concerns regarding reliability, adher-
ence, privacy, and user identification.
The different digital assessment instruments discussed in this
review enable different usage. Supervised digital assessment instru-
ments could provide robust outcomes in clinical trials, with benefits
such as automatic recording of response and scoring, making it eas-
ier to follow study protocols, reducing the risk of error, and increas-
ing inter-rater reliability. Remotely administered tests could serve as
a cost-effective pre-screening before more expensive and invasive
examinations, such as lumbar puncture and brain imaging, are recom-
mended. In clinical trials, mobile devices could be used to identify indi-
viduals at greatest risk of cognitive decline, who aremost likely to ben-
efit from a specific intervention. Close follow-up of people’s cognitive
function from their home environment may also enable high-quality
evaluation of interventions.
4.4 Importance of data security, privacy, and
adherence
As an effect of the increasingly digitized cognitive testing, the issue of
data security and privacy issues have been raised by regulatory author-
ities. Pharmaceutical companies have also emphasized the importance
of these issues. One such consideration is the data storage and trans-
mission between servers, crucial when data are to be stored and pro-
cessed on servers that are not under the direct control of the study.
When commercial companies are involved, questions can arise regard-
ing ownership of data and conflicts of interest.
Data protection in the United States is governed by several laws
enacted on federal and state levels (e.g., Patient Safety and Quality
Improvement Act and Health Information Technology for Economic
and Clinical Health Act). In the European Union (EU), the General Data
Protection Regulation (GDPR) governs data storage and processing
in EU countries. It affects scientific cooperation between countries
inside and outside the EU. Technological development places increased
demands on developers and researchers to familiarize themselveswith
regulatory issues, especially now that new types of personal data are
gathered to a greater extent and across country borders.
Finally, an important and necessary focus is to ensure that data
captured remotely, in an uncontrolled environment, is reliable and an
accurate reflection of an individual’s cognitive functioning. Here also
the importance of adherence comes into play and, although there is
increasing evidence that unsupervised testing can be done, large longi-
tudinal health studies also indicate that there are significant problems
with participant attrition. Work remains to ensure valid and reliable
results for participants performing unsupervised testing in large clin-
ical trials.
5 CONCLUSION
This review highlights the wealth of digital assessment instruments
currently being evaluated in preclinical populations. Digital tech-
nology can be used to assess the subtle cognitive decline that
defines biomarker-confirmed preclinical AD. Potential benefits include
increased sensitivity and reliability, and it could add value to individ-
uals through increased accessibility, engagement, and reduced partici-
pant burden. Digital assessmentsmay have clinical trial implications by
optimized screening, facilitating case finding, and providing more sen-
sitive clinical outcomes. Several promising tests are currently in devel-
opment and are undergoing validation, but work remains before many
of these can be considered alongside conventional in-clinic cognitive
assessments. We have begun to understand the reliability and validity
of cognitive assessments obtained in naturalistic environments, which
is required before beginning cognitive testing outside research cen-
ters on a large scale. Last, more feasibility studies investigating poten-
tial barriers for implementation are needed, including the challenges of
adherence, privacy, and data security.
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